Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

This study found that combination therapy with diphenylcyclopropenone and anthralin was more effective for complete hair regrowth in chronic extensive alopecia areata than diphenylcyclopropenone alone, despite more common side effects.

This study found that diphencyprone showed a significant clinical response for treating alopecia areata, while tacrolimus was not effective.

This study identified ABCB6 as the first gene linked to dyschromatosis universalis hereditaria (DUH) in a large Chinese family, suggesting it plays a role in skin pigmentation.

This case study reported significant clinical improvement in a 26-year-old male with dissecting cellulitis of the scalp after treatment with upadacitinib, suggesting that JAK inhibitors may be a promising option for refractory cases, where standard treatments have limited success.

This study provides a comprehensive review of Ayurvedic insights into Darunaka, suggesting that its management principles can still improve quality of life by addressing underlying pathophysiology.

This text is a website user interface and does not include an abstract summary or research findings.

In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

In this study, researchers developed a novel delivery system using hyaluronic acid gels to encapsulate Huperzine A for Alzheimer's treatment, achieving extended release over 20 days and significantly improving pathology and behavior in mice, including enhanced memory and reduced neuroinflammation.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

This study found that patients with alopecia areata in Dubai experience significant disease and economic burdens, especially when comorbid with psychological conditions, despite frequent dermatologist consultations and topical steroid prescriptions.

In this publication, independent scholar Jeffi Chao Hui Wu presents a comprehensive civilization archiving system spanning fourteen domains, highlighting innovative AGI limitations and physiological case reversals, published in ten languages and integrated into global academic infrastructures.

Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.

This study found that external application of DGD activates the Wnt/β-catenin signaling pathway, promoting hair follicle anagen phase entry, and is a more effective and safer treatment for androgenetic alopecia in mice compared to oral administration.

This study discusses the development of a turmeric-based herbal hair removal product named PASIKULA, highlighting its potential to increase the economic value of turmeric and acceptance by consumers.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This article reviews the use of cyclosporine in dermatological conditions, noting its benefits in treating various skin diseases despite known adverse effects like nephrotoxicity and hypertension, and highlights its preferred use over other immunosuppressants due to an early therapeutic response and a good safety profile.

In this study, Yifa compound treatment significantly improved female pattern hair loss and reduced sera DHT and DHEA levels after six months.

This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.

This study observed that while dermoscopic features in alopecia areata for dark-skinned individuals align with existing literature, yellow dots appear more frequently and could help in grading disease severity.

This abstract contains subscription and access information for Wolters Kluwer Health journals but reports no research findings.

In this prospective, placebo-controlled study, the researchers observed a significant reduction in hair shedding in women after applying the combined topical treatment DA-OTC-002, containing synephrine and TAAR agonists, compared to placebo, showing a 62.5% average reduction with no reported adverse events.

In this series, patients experienced alopecia with limited regrowth following mesotherapy, indicating possible lasting aesthetic consequences and suggesting the need for careful technique and close follow-up, as the condition might be underrecognized.

This study found that dermoscopy can be a useful tool for diagnosing androgenetic alopecia, particularly in determining hair diameter diversity as an essential feature in Asian populations.

This study reviewed existing articles to assess the efficacy of topical diphenylcyclopropenone immunotherapy for alopecia areata, but it did not report new clinical results.

Alopecia areata often recurs after treatment with diphenylcyclopropenone.